Importing Pharmaceuticals into the UK: A Practical Guide
The UK is a major pharmaceutical market and clinical-trial base, but since leaving the EU its import regime has diverged. Great Britain (England, Scotland and Wales) now sits outside the EU, while Northern Ireland continues to follow EU rules under the Windsor Framework, so a single country can present two import regimes. This guide covers who regulates UK imports, the licences an importer needs, how investigational product moves, and where consignments get held.
Who regulates pharmaceutical imports into the UK
Medicines in the UK are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA licenses importers, wholesalers and manufacturers, authorises products and clinical trials, and inspects for good manufacturing and good distribution practice. Since Brexit, Great Britain treats imports from outside the UK, including from the EU, largely as third-country imports, while Northern Ireland remains aligned with EU rules under the Windsor Framework.
What the importer needs
- A Wholesale Dealer's Licence, WDA(H), to import and distribute authorised medicines by wholesale.
- A Manufacturer's or Importer's Authorisation, MIA, with QP oversight where products are imported from a third country and require certification or testing on entry to the UK.
- GDP compliance with a Responsible Person named on the licence.
- Customs clearance for imports into Great Britain, declared through the customs system, with the commercial or proforma invoice and tariff classification.
The UK operates arrangements that allow QP certification and batch testing performed in listed countries, including the EU, to be recognised on import under defined conditions, which reduces duplicate testing for many products. The precise route depends on the product and its origin.
| Document | Purpose |
|---|---|
| Wholesale Dealer's Licence, WDA(H) | Evidence the importer may import and distribute by wholesale. |
| MIA and QP certification where required | Batch certification for third-country imports. |
| Marketing authorisation or trial reference | Shows the product is authorised or moving under a trial. |
| GDP evidence and Responsible Person | Distribution quality and accountability. |
| Commercial or proforma invoice | Customs valuation and description. |
| Temperature record | Cold-chain evidence for temperature-sensitive products. |
Clinical trial material
Import of investigational medicinal product into the UK requires a Manufacturer's or Importer's Authorisation for IMPs, MIA(IMP), with QP oversight of each imported batch. The trial itself needs a Clinical Trial Authorisation from the MHRA and a favourable opinion from a research ethics committee before material moves. The UK has been reforming its clinical-trials framework, so confirm the current route for your trial.
Cold chain and special categories
- Cold chain. Continuous temperature data and a documented excursion response are expected under GDP.
- Controlled drugs. These require a Home Office licence and import authority on top of the medicines licence.
- Dangerous goods. Dry ice and certain biologicals require the correct transport declaration.
Where shipments get held up
- 1The importer does not hold the correct WDA(H) or MIA for the product and its origin.
- 2QP certification for a third-country batch is missing or cannot be recognised on the intended route.
- 3A Great Britain versus Northern Ireland routing question has not been resolved, changing which rules apply.
- 4Temperature data has a gap, forcing a quality decision.
- 5Controlled-drug or dangerous-goods documentation is incomplete.
Frequently asked questions
To import and distribute authorised medicines by wholesale you need a Wholesale Dealer's Licence, WDA(H). For many third-country imports you also need a Manufacturer's or Importer's Authorisation, MIA, with Qualified Person oversight. A Responsible Person must be named and GDP applies throughout.